NanoLogix Inc. has begun construction on a 2,800 square foot manufacturing facility at its headquarters in Hubbard, OH. It will contain a production cleanroom, cold-storage vault, and shipping and receiving area to be used in the fabrication of BNP(TM) Ultra-Fast test kits.
The revolutionary new BNP(TM) kits provide accelerated detection of bacteria and pathogens - 100% to 600% faster than conventional Petri plate testing. They will have broad applications in Homeland Security, human and veterinary medicine, processing and safety of food, cosmetics and drugs, research and development, and industrial and environmental testing.
One of the foremost bio-defense and biomedical research centers in the U.S. recently found in its tests that the BNP(TM) provided results up to four times faster than current Petri plate methods. Using the BNP(TM) they were able to view anthrax cultures in one-quarter of the time, and bubonic plague (Black Death) cultures in half of the time possible with the best traditional methods. The study appears in the current online issue of Letters in Applied Microbiology. Link to study:
http://nanologix.com/downloads/NNLX_resource_3.pdf
The new facility will replace the company's current limited-production operation at its research and development laboratory in Cincinnati, boosting production capability to thousands of BNP(TM) kits per day. This provides the opportunity for expanded R&D of other NanoLogix products at the Cincinnati lab.
The BNP(TM) kit is based on NanoLogix's revolutionary sandwiched-membrane Petri technology. The company believes the BNP(TM) has a high potential of capturing a significant percentage of the annual multi-billion dollar Petri plate market in both the United States and internationally.
NanoLogix CEO Bret Barnhizer stated: "With the BNP(TM) kits, we believe we are on our way to establishing a new 'gold Standard' for microorganism detection that will have a revolutionary effect on medical testing, diagnosis and treatment. This production facility will enable us to capitalize on our technology and provide product to those who are rapidly becoming aware of the BNP(TM) potential".
The test kits provide users the ability for faster detection of a long list of pathogens, including E-coli, Salmonella, Listeria, Enterobacter, Staphylococcus, Anthrax and Bubonic plague.
In addition to providing ultra-fast viewing of microorganisms normally cultured on standard Petri plates, the BNP(TM) kits can be used to assist in early detection of some of the most dangerous pathogens in the world, including those that pose significant potential threats for use as bio-weapons by terrorists.
The BNP(TM) production operation is expected to create a dozen jobs in the economically depressed Youngstown, Ohio, area, with more to follow as product demand increases.
Get curated news on YOUR industry.
Enter your email to receive our newsletters.
Latest from Today's Medical Developments
- Discover cutting-edge machining at SW North America's Open House
- Maximize efficiency: ROBOGUIDE V10's high-performance upgrades
- #47 Lunch + Learn Podcast with INSACO
- USC engineers develop groundbreaking wireless implant for chronic pain management
- WALTER tool making and measuring line: VISION LASER
- Holistic development of medical devices
- Mitutoyo unveils hybrid Hybrid FORMTRACER Avant H-3000 and Formtracepak v6.2 software for precision measurements
- Meet digits: The future of adaptive haptic interfaces